Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non Therapeutic Body Modification Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2

NCT03743064
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
anamorelin HCl, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821
View directory record Official record
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

NCT04599504
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Lisdexamfetamine Dimesylate (Medication), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

NCT00039195
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 25, 2026, 5:12 PM EDT
Active, not recruiting Not applicable Interventional Results available

Lymphocyte Depletion and Change in Lymphocyte Functionality

NCT04273893
View directory record Official record
Conditions
Lymphocyte Depletion
Interventions
SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
Radiation · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1

NCT03743051
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
Anamorelin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

NCT01433263
View directory record Official record
Conditions
Cachexia
Interventions
BYM338 active drug, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 25, 2026, 5:12 PM EDT
Terminated Not applicable Interventional Results available

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

NCT00769652
View directory record Official record
Conditions
Lung Cancer, Malnutrition, Pancreatic Cancer, Prostate Cancer, Weight Changes
Interventions
Medical nutrition therapy, Standard Care
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals

NCT01862796
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Underfeeding diet, Weight maintaining diet
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

NCT01395914
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
19
States / cities
Corona, California • Fountain Valley, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Not applicable Interventional Results available

ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss

NCT02518685
View directory record Official record
Conditions
Obesity
Interventions
TransPyloric Shuttle, Sham procedure, Lifestyle Counseling
Device · Behavioral
Lead sponsor
BaroNova, Inc.
Industry
Eligibility
22 Years to 60 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 25, 2026, 5:12 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations

NCT00487344
View directory record Official record
Conditions
Obesity
Interventions
Non-Personalized Meal Planning, Personalized Meal Planning and Dietetic Consultation
Procedure
Lead sponsor
Central FITT, Inc
Other
Eligibility
25 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Edmond, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 3, 2007 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 1 Interventional Results available

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions
PF-06946860, Placebo for PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 25, 2026, 5:12 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 3 Interventional

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

NCT00031785
View directory record Official record
Conditions
Anorexia, Cachexia, Lung Cancer
Interventions
megestrol acetate, radiation therapy
Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 25, 2026, 5:12 PM EDT
Completed No phase listed Observational

Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer

NCT03091816
View directory record Official record
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
Interventions
Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
Device · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 3 Interventional

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

NCT00040885
View directory record Official record
Conditions
Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions
infliximab, docetaxel, placebo
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
188
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 25, 2026, 5:12 PM EDT
Active, not recruiting Early Phase 1 Interventional Results available

Ruxolitinib for Cancer Cachexia

NCT04906746
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Cachexia
Interventions
Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
Drug
Lead sponsor
Tu Dan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 5:12 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

NCT03991962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 25, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Regimen for the Treatment of Cachexia in Subjects With NSCLC

NCT00527319
View directory record Official record
Conditions
Cachexia
Interventions
VT-122 low dose, VT-122 high dose
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 25, 2026, 5:12 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 25, 2026, 5:12 PM EDT